Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Amortization of Deferred Charges (2019 - 2021)

Anika Therapeutics (ANIK) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $400000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Amortization of Deferred Charges fell 2.68% to $400000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $1.7 million, a 18.95% increase, with the full-year FY2020 number at $1.5 million, up 29.86% from a year prior.
  • Amortization of Deferred Charges was $400000.0 for Q3 2021 at Anika Therapeutics, down from $507000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $507000.0 in Q2 2021 to a low of $289000.0 in Q3 2019.
  • A 3-year average of $365636.4 and a median of $385000.0 in 2020 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: skyrocketed 42.21% in 2020, then fell 2.68% in 2021.
  • Anika Therapeutics' Amortization of Deferred Charges stood at $299000.0 in 2019, then soared by 32.11% to $395000.0 in 2020, then increased by 1.27% to $400000.0 in 2021.
  • Per Business Quant, the three most recent readings for ANIK's Amortization of Deferred Charges are $400000.0 (Q3 2021), $507000.0 (Q2 2021), and $405000.0 (Q1 2021).